Profile data is unavailable for this security.
About the company
Cosmo Pharmaceuticals N.V. is a pharmaceutical company. The Company is focused on gastrointestinal (GI) diseases and dermatology. Its development pipeline is focused on Bowel Diseases, Colon Infections, and products to reduce the incidence of Colorectal Cancer (CRC) by increasing the detection of cancerous and pre-cancerous lesions during colonoscopy. Products which it has developed include Lialda/Mezavant/Mesavancol and Uceris/Cortiment, for the treatment of ulcerative colitis; GI Genius, which uses artificial intelligence to aid the detection of colorectal polyps during colonoscopy; Eleview, a submucosal injectable composition for use in gastrointestinal endoscopic procedures; Aemcolo for the treatment of travellers’ diarrhoea (TD), Methylene Blue MMX, which is a new diagnostic drug to improve precancerous and cancerous lesion detection during colonoscopy and Winlevi for the treatment of acne. Its therapeutic focus is on the oral and endoscopic treatment of colon diseases.
- Revenue in CHF (TTM)174.19m
- Net income in CHF65.38m
- Incorporated--
- Employees339.00
- LocationCosmo Pharmaceuticals NVRiverside II, Sir John Rogerson's QuayDUBLIN IrelandIRL
- Phone+353 18170370
- Websitehttps://www.cosmopharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AIM Vaccine Co Ltd | 143.78m | -144.47m | 1.13bn | 1.56k | -- | 2.66 | -- | 7.87 | -1.07 | -1.07 | 1.07 | 3.16 | 0.1462 | 0.6325 | 1.10 | 796,290.20 | -22.69 | -- | -37.16 | -- | 72.34 | -- | -155.22 | -- | 0.6836 | -6.61 | 0.3437 | -- | -6.06 | -- | -307.07 | -- | -- | -- |
| Nanjing Vazyme Biotech Co Ltd | 170.72m | 2.87m | 1.14bn | 2.70k | 379.98 | 2.34 | -- | 6.67 | 0.0615 | 0.0615 | 3.84 | 9.97 | 0.2644 | 1.06 | 3.57 | 519,483.10 | 0.4122 | 13.16 | 0.5237 | 15.92 | 70.21 | 70.50 | 1.56 | 23.92 | 4.17 | -- | 0.1436 | 32.20 | -63.97 | 49.74 | -111.94 | -- | 48.61 | -- |
| Shenzhen Chipscreen Biosciences Co Ltd | 79.88m | -8.56m | 1.14bn | 1.06k | -- | 5.72 | -- | 14.32 | -0.1709 | -0.1709 | 1.60 | 4.03 | 0.2022 | 2.34 | 4.47 | 620,847.90 | -2.17 | 1.32 | -2.44 | 1.54 | 86.24 | 93.29 | -10.72 | 6.97 | 2.76 | -0.5584 | 0.441 | 0.00 | -1.18 | 28.81 | 408.09 | 23.31 | 10.23 | -- |
| Guangxi Wuzhou Zhongheng Group Co Ltd | 347.83m | -3.04m | 1.15bn | 2.89k | -- | 1.45 | -- | 3.30 | -0.0074 | -0.0074 | 0.8379 | 1.89 | 0.2476 | 2.17 | 4.52 | 990,180.10 | -0.3138 | 2.26 | -0.4836 | 3.38 | 42.33 | 72.05 | -1.27 | 7.27 | 2.39 | -- | 0.1767 | 45.67 | 14.10 | -1.26 | 6.69 | -32.76 | -4.56 | -30.12 |
| Sanofi Consumer Healthcare India Ltd | 82.23m | 23.69m | 1.15bn | -- | 48.65 | 60.80 | 47.90 | 14.02 | 100.17 | 100.17 | 347.67 | 80.15 | -- | -- | -- | -- | -- | -- | -- | -- | 71.64 | -- | 28.81 | -- | 2.27 | 3,260.00 | 0.0986 | -- | -- | -- | -- | -- | -- | -- |
| Luye Pharma Group Ltd | 766.55m | 93.55m | 1.16bn | 5.23k | 12.39 | 0.7329 | 6.15 | 1.51 | 0.2237 | 0.2237 | 1.83 | 3.78 | 0.236 | 2.44 | 3.02 | 1,308,291.00 | 3.11 | 2.80 | 5.47 | 4.45 | 68.73 | 70.53 | 13.18 | 10.39 | 1.20 | 3.14 | 0.4103 | 11.82 | 2.70 | 3.50 | -11.94 | -16.39 | -14.05 | -- |
| Cosmo Pharmaceuticals NV | 174.19m | 65.38m | 1.17bn | 339.00 | 16.41 | 2.28 | 14.72 | 6.71 | 4.06 | 4.06 | 10.83 | 29.19 | 0.2696 | 3.19 | 6.45 | 535,977.70 | 10.16 | 0.0615 | 12.44 | 0.0674 | 76.47 | 56.84 | 37.68 | 0.535 | 4.48 | -- | 0.0029 | 3,947.26 | -9.12 | 7.17 | -128.63 | -- | 9.62 | -- |
| GuangYuYuan Chinese Herbal Medicn Co Ltd | 150.90m | 16.62m | 1.17bn | 1.81k | 70.33 | 6.13 | -- | 7.75 | 0.279 | 0.279 | 2.53 | 3.20 | 0.5011 | 0.5647 | 2.60 | 684,557.40 | 6.04 | -2.10 | 8.71 | -3.16 | 72.21 | 69.74 | 12.05 | -6.00 | 0.9873 | 21.00 | 0.0267 | -- | 13.56 | -4.53 | 136.03 | -24.78 | -58.35 | -- |
| Genomma Lab Internacional SAB de CV | 750.59m | 68.87m | 1.17bn | 1.63k | 15.81 | 2.27 | 14.55 | 1.57 | 1.69 | 1.69 | 18.48 | 11.80 | 0.7663 | 2.81 | 3.85 | 10,695,950.00 | 7.03 | 5.79 | 10.00 | 8.64 | 63.56 | 61.70 | 9.18 | 7.88 | 1.56 | 3.96 | 0.3738 | 16.85 | -2.10 | 6.90 | -21.90 | -0.4465 | -26.37 | -- |
| Cansino Biologics Inc | 91.11m | -87.65m | 1.19bn | 1.49k | -- | 2.73 | -- | 13.06 | -2.92 | -2.92 | 3.03 | 20.46 | 0.0851 | 0.6341 | 1.12 | 501,023.80 | -8.41 | -4.27 | -11.09 | -5.59 | 67.71 | 41.73 | -98.82 | -27.60 | 2.27 | -8.75 | 0.2934 | -- | -65.49 | 163.48 | -63.04 | -- | 30.60 | -- |
| North China Pharmaceutical Co Ltd | 1.18bn | 9.66m | 1.20bn | 10.16k | 123.15 | 1.83 | -- | 1.01 | 0.0465 | 0.0465 | 5.68 | 3.13 | 0.4492 | 2.67 | 4.34 | 955,385.00 | 0.6731 | -0.2978 | 1.54 | -0.7042 | 29.79 | 35.73 | 1.50 | -0.5985 | 0.5609 | 1.64 | 0.6482 | -- | -3.62 | 1.89 | 100.71 | -49.62 | 4.22 | -19.73 |
Data as of Nov 05 2024. Currency figures normalised to Cosmo Pharmaceuticals NV's reporting currency: Swiss Franc CHF
8.79%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| UBS Asset Management Switzerland AGas of 16 Aug 2023 | 524.55k | 2.99% |
| The Vanguard Group, Inc.as of 02 Oct 2024 | 339.93k | 1.94% |
| Z�rcher Kantonalbank (Investment Management)as of 30 Aug 2024 | 176.49k | 1.01% |
| BlackRock Fund Advisorsas of 02 Oct 2024 | 115.15k | 0.66% |
| Baillie Gifford & Co.as of 30 Sep 2024 | 104.44k | 0.60% |
| Dimensional Fund Advisors LPas of 03 Oct 2024 | 78.88k | 0.45% |
| JPMorgan Asset Management (UK) Ltd.as of 30 Sep 2024 | 65.95k | 0.38% |
| Norges Bank Investment Managementas of 30 Jun 2024 | 63.20k | 0.36% |
| 3V Asset Management AGas of 30 Apr 2024 | 41.66k | 0.24% |
| Deka Investment GmbHas of 30 Jun 2024 | 31.65k | 0.18% |
More ▼
Data from 30 Apr 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
